Autologous Myoblast Intrasphincteric Injection for Fecal Incontinence

after verification of information and inclusion criteria. patients were randomized to treatment or placebo arms and receive the injections.

an evaluation of the function and quality of life are realized. after a period of 6 months, patients in the placebo arm receive the injection of myoblasts that have been preserved.

Inclusion criteria

• age between 20 and 65 years
• severe fecal incontinence from at least three months
• Jorge et Wexner score ≥ 10
• incontinence refractory to medical treatment and to reeducation from at least three months
• incontinence due to lesion of the external anal sphincter
• incontinence without significant anal sphincter rupture or rupture ≤ 30% of circumference assessed by endo-anal ultra-sonography
• integrity or not of the internal anal sphincter
• fecal incontinence with normal rectum capacity (maximum tolerable volume ≥ 150 ml assessed by ano-rectal manometry)
• fecal incontinence without associated rectal static disorder on defeco-MRI
• fecal incontinence without bilateral complete neuropathy assessed by electro-physiology

Exclusion criteria

• fecal incontinence with rupture > 30 % of the external anal sphincter
• fecal incontinence with bilateral lesions on the sacral nerves
• Crohn's disease or ulcerative colitis
• unstable type 1 or type 2 diabetes
• myopathy
• peripheral or central neurological diseases
• treatment with laxatives, suppositories or enema
• practice of anal intercourse except if stopped during the study
• treatment with immunosuppressive or cytostatic drugs, CoA HMG reductase inhibitors, morphine derivatives
• treatment of constipation or rectal dyschesia
• pregnancy or breast-feeding,lack of effective contraception during the study (female)
• allergy to antibiotics (cephalexin, metronidazole)